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J Sex MedIntroduction: Hypogonadism in men is often associated with poor libido, erectile dysfunction, irritability,
fatigue, and psychological and relationship problems. Many of these symptoms can be best assessed through
patient report. The 28-item Hypogonadism Impact of Symptoms Questionnaire (HIS-Q) was developed to
evaluate hypogonadism symptoms in men with low testosterone in the context of clinical trials.
Aim: To develop a briefer version of the HIS-Q that could be practical for use in treatment settings.
Methods: Participants with low testosterone levels and symptoms consistent with hypogonadism were recruited
through clinical sites. Focus groups and interviews were conducted to elicit symptom concepts and identify those
that were most relevant to patients, including changes as a consequence of treatment.
Main Outcome Measures: Systematic analysis of the qualitative data and expert clinician input were used to
develop the HIS-Q short form (HIS-Q-SF). One-on-one cognitive interviews were conducted to conﬁrm the
content validity of the HIS-Q-SF.
Results: Thirty-ﬁve men participated in this qualitative research. Concept elicitation was conducted through
focus group discussions (n ¼ 18) and telephone interviews (n ¼ 2); then, the draft HIS-Q-SF was evaluated
through cognitive interviews (n ¼ 15). The mean age of total sample was 53.2 ± 6.8 years, and the mean serum
total testosterone level was 184.9 ± 55.2 ng/dL. Results suggest that the HIS-Q-SF has demonstrated content
validity, including the content coverage, comprehensibility, and the appropriateness of the response options and
recall period. The ﬁnal version of the HIS-Q-SF includes 17 items and is aligned with the original longer version
of the instrument.
Conclusion: The HIS-Q-SF is a comprehensive measurement of hypogonadism symptom severity in men.
Content coverage and content validity were conﬁrmed. The instrument will be evaluated further to establish the
psychometric characteristics and to assess the utility of the measurement in clinical treatment settings.
J Sex Med 2016;13:1729e1736. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the
International Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Hypogonadal (low testosterone or testosterone deﬁciency)
symptoms and their subsequent effects have substantial negative
effects on the functioning and quality of life of affected men.1,2
Findings from the Massachusetts Male Aging Study suggested
that approximately 2.4 million men 40 to 69 years old have some
degree of hypogonadism.3 Once believed to affect primarily
sexual functioning, androgens are now known to have a much
broader impact on target organ systems such as bone, muscle,
and cardiovascular and brain functioning, with lower levels being1729
1730 Gelhorn et alassociated with poor libido, erectile dysfunction, irritability,
fatigue, and psychological and relationship problems.4e6
Clinical trials evaluating treatments for hypogonadism often
incorporate self-reported outcomes from patients, commonly
referred to as patient-reported outcomes (PROs). PROs are
useful because many of the signs and symptoms of hypogonad-
ism (eg, low libido, fatigue) are known only to patients and
cannot be evaluated through clinical assessments or tests.7
Although existing instruments have been used to assess the
symptoms of low testosterone in men, none have been specif-
ically designed to comprehensively measure symptoms and
effects in this patient population. In addition, many measure-
ments currently being used were developed without any input
directly from patients. To address this gap, the Hypogonadism
Impact of Symptoms Questionnaire (HIS-Q) was developed to
assess changes in symptom frequency and severity in the context
of clinical trials.4,8 The HIS-Q is comprised of 28 items and was
developed according to Food and Drug Administration guid-
ance9 for the development of PRO measurements. This guidance
emphasizes the importance of soliciting input directly from
patients during the development of PRO instruments to ensure
that the measurements are meaningful and relevant to patients.
The objective of the present study was to develop and establish
the content validity of a shorter version of the HIS-Q (the HIS-Q
Short Form [HIS-Q-SF]) that would be more suitable for use in
clinical practice. The developmental work for the original HIS-Q
included focus groups and interviews with 65 participants of
diverse clinical and demographic characteristics,4 and the present
work builds on this previous body of evidence by focusing more
speciﬁcally on patients’ experiences with changes in hypo-
gonadism symptoms after testosterone replacement therapy
(TRT). Qualitative work with patients is often helpful when
developing or adapting a new PRO instrument to ensure that the
measurement’s content and format are consistent with patients’
experiences. In particular, the study team wanted direct patient
input on the relevance of individual symptoms and the impor-
tance of changes in these symptoms after TRT. This was ach-
ieved by conducting a qualitative study to identify the most
important symptoms, to understand changes in symptoms as a
result of treatment, and to establish the content validity of the
draft HIS-Q-SF in patients with low testosterone. This initial
qualitative work is the ﬁrst step in developing a PRO instrument;
once a draft version of the instrument is available, the psycho-
metric properties can be established and then the instrument can
be used to track changes in symptom severity throughout
treatment.METHODS
Study Design and Procedures
A two-part cross-sectional qualitative study involving (i)
semistructured focus groups and one-on-one interviews and (ii)
cognitive interviews through similar methods with a total of 35adult male patients with hypogonadism was conducted. Part 1
included concept elicitation focus groups and discussions to
solicit spontaneous input on patients’ hypogonadism experi-
ences, including sorting hypogonadism symptoms in order of
importance. Part 2 involved cognitive interviews on the newly
created draft version of the HIS-Q-SF that focused on partici-
pants’ understanding of the items, decision processes about the
responses, interpretation of response options, and understanding
and evaluating recall period appropriateness (ie, whether the
suggested recall time for the questions was deemed reasonable
and appropriate by the participants). The study included
in-person and telephone discussions. Participants took part in
only one stage of the research process (part 1 or 2).
Participants were recruited through three clinical sites located
in New Jersey, New York, and Washington State from
November 2013 through November 2014. The study was
reviewed and approved by an institutional review board and all
participants provided informed consent. Inclusion criteria were
the same for the two parts of the study and included men 18 to
65 years of age; a history of signs and symptoms consistent with a
diagnosis of hypogonadism; serum total testosterone concentra-
tion lower than 300 ng/dL; able to read, speak, and understand
English; willing and able to attend and participate in a discussion
on the topic; willing to provide informed consent; and were
currently receiving or had previously received TRT within the
past 2 years. Participants were remunerated a modest amount at
completion of the study.Part 1: Concept Elicitation
A discussion guide was developed for the concept elicitation
portion of the interview based on a review of the literature, prior
research by the investigators in the development of the original
HIS-Q, and input from clinical experts. The discussion guide
was designed to elicit patients’ symptom experiences and changes
in these symptoms in response to treatment. Focus group and
interview sessions were audio-recorded with the participants’
permission.
The sessions began with emergent discussion of hypogonad-
ism symptoms followed by symptom ranking exercises. These
ranking exercises were designed to identify (i) which symptoms
were of greatest importance or relevance to the patients overall
and (ii) which symptoms were important for improvement as a
result of treatment. To complete the symptom ranking exercise,
participants were asked to prioritize three mood symptom
concepts that were most relevant to them from a list of 16 mood
concepts identiﬁed through prior qualitative research. Then,
participants were given 18 cards, each of which displayed a
common symptom of hypogonadism (including the three mood
concepts they had just selected as most relevant). These symp-
toms represented the major concepts that were identiﬁed during
the qualitative development of the original HIS-Q and were
selected based on prior qualitative research and input from expert
clinicians. Participants were asked to select the ﬁve symptomJ Sex Med 2016;13:1729e1736
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they were given 18 duplicate cards and subsequently asked to the
select ﬁve symptoms that reﬂected the most important changes
associated with testosterone treatments.Part 2: Cognitive Interviews
One-on-one cognitive interviews were conducted with a new
group of participants recruited by two clinical sites (in New York
and New Jersey) using a standardized screening script. In-person
interviews were conducted at the clinical sites and all interviews
were audio-recorded with the participants’ permission. Partici-
pants were asked to complete the draft 17-item HIS-Q-SF at the
start of the interview. A semistructured interview discussion
guide was used to assess the clarity of the HIS-Q-SF, the ease of
completing the measurement, and the appropriateness of the
format and response scales and recall period.
Measurements
After the concept elicitation discussions and symptom
ranking exercise, participants in part 1 completed the Interna-
tional Index of Erectile Function Questionnaire (IIEF), the
Aging Males’ Symptoms Scale (AMS), and a sociodemographic
and clinical questionnaire. Participants in part 2 completed the
draft HIS-Q-SF, the AMS, and the sociodemographic and
clinical questionnaire.
The IIEF is a 15-item self-administered measurement of male
sexual functioning.10 The items are designed to detect treatment-
related changes in patients with erectile dysfunction and are
divided into ﬁve domains of sexual function: erectile dysfunction
(six items), orgasmic function (two items), sexual desire (two
items), intercourse satisfaction (three items), and overall satis-
faction (two items). The recall period for all IIEF items is 4
weeks. The AMS is a 17-item scale that evaluates symptoms
related to low testosterone including difﬁculty sleeping, low
energy, physical symptoms, and effects on sexual functioning and
mood.11 This self-administered instrument asks participants to
rate current symptoms on a ﬁve-point response scale (none to
extremely severe). The sociodemographic and clinical question-
naire assessed characteristics such as age, sex, race, employment
status, education, relationship status, and overall health. The
clinical case report form was completed by site staff and collected
information about a patient’s hypogonadism diagnosis, treatment
history, and comorbid conditions.
Analysis
Descriptive statistics (mean, SD, and frequency) were used to
characterize the sample for sociodemographic and clinical
characteristics and to summarize data collected from the
symptom ranking exercise, HIS-Q, AMS, and IIEF.
Transcripts from the focus groups and interviews were
analyzed with ATLAS.ti 7.0.71 (http://atlasti.com) using an
open coding approach. A coding dictionary was developed based
on the semistructured interview guide to assist with the reviewJ Sex Med 2016;13:1729e1736and analysis of the data. Participant quotations were grouped and
summarized by thematic code, and saturation was evaluated for
the concept elicitation data. Saturation is deﬁned as the point at
which no substantially new themes, descriptions of a concept, or
terms are introduced as additional focus groups or interviews are
conducted.12RESULTS
Sample Description
Twenty men participated in concept elicitation through three
focus groups (n ¼ 18) and two interviews (n ¼ 2); 15 men
participated in the cognitive interviews. Participants’ mean age
was 53.2 ± 6.8 years (range ¼ 35 to 64), and most were white
(71.4%; Table 1). The mean time since hypogonadism diagnosis
was 2.9 ± 3.9 years (range ¼ 0.3e20.6), and mean minimum
serum total concentration was 184.9 ± 55.2 ng/dL. In total,
91.4% of participants had previously received TRT and 88.6%
were currently receiving TRT. The participants’ mean body mass
index was 31.3 ± 5.4 (range ¼ 23.7e44.1; Table 2).
The AMS was administered for descriptive purposes; mean
AMS subscale scores indicated that the sample had “severe”
sexual impairment (12.3 ± 5.2), “moderate” psychological
impairment (9.0 ± 4.1), and “moderate” somatic impairment
(15.7 ± 5.4; Aging Male Norm Values, accessed July 16, 2014).
The IIEF was administered in part 1 (n ¼ 20), and scores
indicated moderate levels of dysfunction (erectile function,
mean ¼ 12.7 ± 5.8; orgasmic function, mean ¼ 3.8 ± 2.9;
sexual desire, mean ¼ 4.7± 2.6; intercourse satisfaction,
mean ¼ 5.8 ± 3.8; overall satisfaction, mean ¼ 6.1 ± 3.1).10Part 1: Concept Elicitation Results
Participants described their symptoms of low testosterone
using terms that were highly consistent with the literature and
prior studies.4 Spontaneously reported symptoms included low
sex drive or low sexual desire; inability to complete the sexual act;
difﬁculty maintaining an erection; low or no energy; tired; lazy;
lack of stamina; fatigue; mood swings (angry, impatient, short);
lack of focus; difﬁculty concentrating; confusion; lack of moti-
vation; trouble losing weight; gaining weight more easily;
inability to build muscle; lack of muscle strength or decreased
muscle strength; depression; anxiety; less intense climax or
orgasm; and change in sensitivity of genitals.
Results from the symptom ranking exercise suggested that
energy level (n ¼ 10, 50%) and sexual desire (n ¼ 10, 50%)
were the most relevant symptoms (Table 3). In addition, many
other sexual symptoms (sexual enjoyment, ability to maintain an
erection, ability to achieve an erection, frequency of sexual
activities, hardness of erections, and sexual satisfaction) were
frequently ranked in the top ﬁve. Motivation and concentration
or focus were included in the top ﬁve ranking of 25% of the
participants. For the most important changing symptoms, energy
level and sexual desire were the top two (n ¼ 12, 60%; Table 3).
Table 1. Participant sociodemographic characteristics
Concept elicitation (n ¼ 20) Cognitive interview (n ¼ 15) Total (N ¼ 35)
Age (y)
Mean (SD) 52.9 (7.7) 53.7 (5.6) 53.2 (6.8)
Range 35.0e63.0 42.0e64.0 35.0e64.0
Ethnicity, n (%)
Hispanic or Latino 1 (5.0) 2 (13.3) 3 (8.6)
Not Hispanic or Latino 18 (90.0) 13 (86.7) 31 (88.6)
Missing 1 (5.0) 0 (0.0) 1 (2.9)
Race, n (%)*
American Indian or Alaska Native 2 (10.0) 0 (0.0) 2 (5.7)
Asian 0 (0.0) 0 (0.0) 0 (0.0)
Black or African American 4 (20.0) 3 (20.0) 7 (20.0)
White 15 (75.0) 10 (66.7) 25 (71.4)
Other† 0 (0.0) 1 (6.7) 1 (2.9)
Missing 1 (5.0) 1 (6.7) 2 (5.7)
Current living or domestic situation, n (%)
Living alone 3 (15.0) 3 (20.0) 6 (17.1)
Living with partner or spouse, family, or friends 16 (80.0) 12 (80.0) 28 (80.0)
Other‡ 1 (5.0) 0 (0.0) 1 (2.9)
Employment status, n (%)
Full-time work 10 (50.0) 11 (73.3) 21 (60.0)
Part-time work 0 (0.0) 1 (6.7) 1 (2.9)
Retired 5 (25.0) 3 (20.0) 8 (22.9)
Disabled 3 (15.0) 0 (0.0) 3 (8.6)
Other§ 2 (10.0) 0 (0.0) 2 (5.7)
Education status, n (%)
Secondary or high school 5 (25.0) 5 (33.3) 10 (28.6)
Some college 6 (30.0) 4 (26.7) 10 (28.6)
College degree 8 (40.0) 3 (20.0) 11 (31.4)
Postgraduate degree 1 (5.0) 3 (6.7) 4 (11.4)
Currently in intimate relationship, n (%)
Yes 19 (95.0) 15 (100) 34 (97.1)
No 1 (5.0) 0 (0.0) 1 (2.9)
Length of relationship (y), mean (SD) 20.4 (11.1) 22.2 (13.1) 21.2 (11.8)
*Not mutually exclusive.
†Puerto Rican.
‡Part-time relationship.
§Employed part time or retired or self-employed.
1732 Gelhorn et alSexual satisfaction (n ¼ 8, 40%), ability to maintain an erection
and ability to achieve an erection (n ¼ 6 for each, 30%), and
tired (n ¼ 5, 25%) were the remaining symptoms selected as
most important by at least 25% of participants. Results of the
concept elicitation focus groups and one-on-one interviews were
documented in a saturation grid and demonstrated saturation of
concepts and symptoms of low testosterone, indicating that the
sample size was appropriate.
Development of the Initial Draft HIS-Q-SF
Seventeen HIS-Q items were selected for the draft version of
the HIS-Q-SF. The selected items were consistent with the re-
sults of the concept elicitation phase of work and data from the
original HIS-Q qualitative work. Consideration was given to the
prevalence of the concepts, patients’ reports on the relevance andimportance of changes in symptoms, and input from clinicians.
Instructions were drafted and response options were adapted
from the full-length HIS-Q. Items selected for inclusion in the
short form consisted of eight items from the sexual symptoms
domain, two items from the energy domain, two items from the
sleep domain, two items from the cognition domain, and three
items from the mood domain. The response options were the
same as those on the original HIS-Q and instructions were
adapted to ﬁt the newly created HIS-Q-SF.Part 2: Cognitive Interview Results
Content validity and relevance of the HIS-Q-SF was estab-
lished through cognitive interviews. The interviews conﬁrmed
that the subset of the original HIS-Q items selected for the shortJ Sex Med 2016;13:1729e1736
Table 2. Participant clinical characteristics
Concept elicitation (n ¼ 20) Cognitive interview (n ¼ 15) Total (N ¼ 35)
Minimum serum total testosterone concentration (ng/dL)
Mean (SD) 202.0 (54.9) 162.1 (48.4) 184.9 (55.2)
Range 91.0e301.0 108.0e280.0 91.0e301.0
Provider-reported hypogonadism etiology, n (%)
Primary acquired 5 (25.0) 13 (86.7) 18 (51.4)
Secondary acquired 1 (5.0) 0 (0.0) 1 (2.9)
Unknown 14 (70.0) 2 (13.3) 16 (45.7)
Time since diagnosis (y)
Mean (SD) 3.4 (4.6) 2.2 (2.6) 2.9 (3.9)
Range 0.3e20.6 0.4e10.3 0.3e20.6
Missing, n (%) 1 (5.0) 0 (0.0) 1 (2.9)
Currently receiving testosterone replacement therapy, n (%)
No 3 (15.0) 1 (6.7) 4 (11.4)
Yes 17 (85.0) 14 (93.3) 31 (88.6)
Previously received testosterone replacement therapy, n (%)
No 2 (10.0) 1 (6.7) 3 (8.6)
Yes 18 (90.0) 14 (93.3) 32 (91.4)
Comorbid conditions*
Anxiety 1 (5.0) 0 (0.0) 1 (2.9)
Cardiovascular disease 2 (10.0) 0 (0.0) 2 (5.7)
Depression 1 (5.0) 1 (6.7) 2 (5.7)
Obesity 2 (10.0) 3 (20.0) 5 (14.3)
Pulmonary disease 1 (5.0) 0 (0.0) 1 (2.9)
Sleep apnea 3 (15.0) 0 (0.0) 3 (8.6)
Other† 6 (30.0) 0 (0.0) 6 (17.1)
Patient’s body mass index
Mean (SD) 31.2 (4.7) 31.4 (6.3) 31.3 (5.4)
Range 23.7e43.1 25.1e44.1 23.7e44.1
*Not mutually exclusive.
†Alcohol abuse, asthma, benign prostatic hyperplasia, diabetes, or hypothyroidism (n ¼ 2).
Development of the HIS-Q-SF 1733form were endorsed by participants and they reported minimal
issues with understanding and completion of the short form.
After an initial round of interviews (n ¼ 9), the HIS-Q-SF
instructions were modiﬁed slightly based on participant input.
The modiﬁed questionnaire and modiﬁed interview guide were
used in the second round of interviews (n ¼ 6).
Finalization of the Draft HIS-Q-SF
The psychometric evaluation of the original HIS-Q was
ongoing while the HIS-Q-SF qualitative work was being con-
ducted. After the ﬁnal HIS-Q item reduction process, two items
in the sleep domain selected for the HIS-Q-SF did not align with
the ﬁnal HIS-Q items. After careful analysis and discussion, these
two sleep items were replaced with sleep items from the ﬁnal
HIS-Q. This replacement was made with the support of the
clinical experts and data from the development of the original
HIS-Q. The ﬁnal items in the sleep domain still captured
important concepts related to sleep, and the change was
considered relatively minor because sleep-related issues arose
much less frequently than concepts in other domain areas
(eg, sexual and energy; Table 3).J Sex Med 2016;13:1729e1736The content validity of the HIS-Q-SF, including the items,
response options, and recall period, was conﬁrmed through focus
groups, cognitive interviews, and clinical expert input. The cur-
rent version of the HIS-Q-SF is a shortened version of the original
HIS-Q and consists of 17 items (Supplementary Appendix A).DISCUSSION
Recently, there has been an increased interest in patient-
centered care, patient-focused drug development, and the
collection of PRO data in clinical settings.13,14 Further, there is
evidence to suggest that integrating PROs into clinical settings
improves communication between patients and their clinicians
and might have positive effects on patient care and out-
comes.15e17 As PROs are increasingly being developed and used
as outcome measurements in clinical trials, it is important that
these instruments are relevant in the clinical trial and treatment
settings. Further, the rationale for the use of PROs in clinical
trials (ie, to demonstrate that clinical measurements of
improvements such as increases in testosterone level correspond
to meaningful improvements in the symptoms that patients
Table 3. Results of symptom ranking exercise
Most relevant symptoms* Total % Most important changing symptoms† Total %
Energy level 10 50 Energy level 12 60
Sexual desire 10 50 Sexual desire 12 60
Sexual enjoyment 9 45 Sexual satisfaction 8 40
Ability to maintain an erection 8 40 Ability to maintain an erection 6 30
Ability to achieve an erection 7 35 Ability to achieve an erection 6 30
Frequency of sexual activities 6 30 Tired 5 25
How hard your erections are 6 30 Depressed 4 20
Motivation 5 25 Frequency of sexual thoughts or fantasies 4 20
Sexual satisfaction 5 25 Ability to ejaculate 4 20
Concentration or focus 5 25 Sexual enjoyment 4 20
Feelings about body appearance or weight 4 20 Memory 3 15
Depressed 3 15 Concentration or focus 3 15
Tired 3 15 Muscle weakness 3 15
Ability to ejaculate 3 15 Feeling masculine 2 10
Memory 3 15 Anxious 2 10
Anxious 2 10 Motivation 2 10
Muscle weakness 2 10 Feel that life is enjoyable 2 10
Conﬁdence 1 5 Frequency of sexual activities 2 10
Moody 1 5 How hard your erections are 2 10
Lonely when you are with others 1 5 Daytime sleep 2 10
Feel like being alone 1 5 Conﬁdence 1 5
Feel that life is enjoyable 1 5 Moody 1 5
Frequency of sexual thoughts or fantasies 1 5 Lonely even when you are with others 1 5
Daytime sleeping 1 5 Feel like being alone 1 5
Sleep quality 1 5 Interest in doing leisure activities 1 5
Sleep quality 1 5
Sleep quantity 1 5
*Moderator instructions: Pick out the ﬁve symptoms or concepts listed on the cards that you believe are most important or relevant to you.
†Moderator instructions: Pick out the ﬁve cards that describe symptoms that have changed that you believe are most important to you. These symptoms
could be important because they changed a lot while you were on treatment, or they could be important because the changes had an important impact for
you, or maybe they are important to you for another reason.
1734 Gelhorn et alexperience) applies in treatment settings. The ability to evaluate
and document changes in symptoms could be of signiﬁcant
clinical value, potentially informing treatment decisions and
contributing to a higher quality of care.
Continuity in the use of PROs across drug development and
treatment settings and ensuring that the measurements are
familiar to treatment providers can facilitate greater meaning-
fulness and interpretability of the PRO outcomes. However, the
characteristics of an appropriate PRO might differ in each
context; clinical versions of the instrument should be short and
easily implemented and interpreted, whereas versions used in
clinical trials might need to be more comprehensive and meet
regulatory requirements. The present study was conducted to
inform the development of the shorter version of the HIS-Q
questionnaire, a measurement initially developed for use as an
end point in registration-level clinical trials. The intention was to
create a shorter version of this patient-reported instrument that is
appropriate for use in clinical settings. The HIS-Q-SF was
developed to provide practicing clinicians with a brief assessment
of hypogonadism symptoms and a practical tool for assessingresponse to TRT. Preliminary analyses comparing the original
HIS-Q with the HIS-Q-SF suggest that the scores from the two
measurements are highly correlated (ie, r  0.91).
For practical reasons, the development of the HIS-Q-SF was
conducted concurrently with ﬁnalization and psychometric
evaluation of the HIS-Q. Results from this quantitative evalua-
tion of the original draft instrument were considered in the ﬁnal
draft version of the HIS-Q-SF.8 Thus, several items that were
selected for inclusion in the ﬁnal version of the HIS-Q were
selected for inclusion in the HIS-Q-SF. Although selecting items
based solely on psychometric data is an option in the develop-
ment of a short form of an instrument, in this case, those data
were supplemented by an additional qualitative study. Gathering
direct patient input to inform the speciﬁc purpose of the shorter
version of the instrument served as a conﬁrmation of prior
development work (ie, no new concepts or symptoms were
identiﬁed) and helped the development team to ensure that the
appropriate items were selected for inclusion. The combined
sample of participants from the original HIS-Q development and
the present study includes an extremely large number ofJ Sex Med 2016;13:1729e1736
Development of the HIS-Q-SF 1735participants in the two qualitative phases of work (concept elic-
itation [n ¼ 56]: original HIS-Q, n ¼ 36; HIS-Q-SF, n ¼ 20;
cognitive interviews [n ¼ 44]: original HIS-Q, n ¼ 29; HIS-Q-
SF, n ¼ 15). These sample sizes are very robust for this type of
research and provide a strong body of supportive evidence for the
content validity of the HIS-Q-SF.
Consistent with other research, the present study found that
most patients selected energy and sexual symptoms as the most
relevant and the most important for changes in response to
treatment.18 This ﬁnding might reﬂect in part a sampling bias
because these two conceptual domains also are the most common
reasons for seeking treatment for low testosterone.19 Regardless,
this highlights for clinicians the importance of carefully assessing
this patient population’s baseline complaints about energy levels
and sexual symptoms and managing expectations regarding the
responsiveness of these symptoms to TRT. Despite the apparent
importance of the sexual and energy domains, the draft version of
the HIS-Q includes questions from the other domains (ie, sleep,
cognition, and mood), because these are important to at least a
subset of patients and could be useful to clinicians by providing a
comprehensive means to evaluate and monitor changes in their
patients’ status across all relevant domains. An interesting area for
future research includes studies that compare samples of eugo-
nadal men with those with testosterone deﬁciencies and clinical
studies of patients that further elucidate the relation between
patients’ testosterone levels and their scores on the HIS-Q and
HIS-Q-SF.
The HIS-Q-SF recall periods of 14 and 7 days for the sexual
domains and other domains, respectively, are consistent with the
original HIS-Q instrument. As described in the article on the
development of the HIS-Q, “participants reported that their
symptoms varied, in some cases daily, but most felt they would
be best recalled over a 1- to 2-week period. The decision to use a
recall period of 2 weeks for the sexual symptoms was prompted
by concerns regarding the frequency of sexual activity for many
men with hypogonadism and reports that accurate recall would
be difﬁcult for a period longer than 2 weeks.”4
Although the HIS-Q-SF data collected in this study were not
scored, a HIS-Q-SF scoring algorithm has been developed. The
HIS-Q-SF scoring algorithm includes each of the 14 ordinal
response scale items and yields ﬁve domain scores (sexual, energy,
sleep, cognition, and mood) and two sexual subdomain scores
(libido and sexual function). A total score also can be calculated.
Scores are scaled from 0 to 100, where higher scores indicate
greater levels of dysfunction. Like the HIS-Q, the open-ended
items (items 1e3) representing numerical response data were
not included in the ﬁnal scoring algorithm but are included
because they might provide useful information on the frequency
of sexual activity.”8
This study had several limitations. First, most of the sample
was white (88%), with fewer participants from minority groups
participating. However, when reviewing a sample of TRT
randomized clinical trials, the demographics of this studyJ Sex Med 2016;13:1729e1736generally matched the distribution of race in TRT randomized
clinical trials, which ranged from 83% to 89% white.20e22
Second, the qualitative data were gathered exclusively from
patients who had been diagnosed with hypogonadism, with no
control or reference group. The extent to which the symptoms
that arose are unique to men with hypogonadism vs symptoms of
the normal process of aging is uncertain; this is an area for future
research. Third, most participants in the study had already
undergone some form of TRT, so their experiences with these
treatments might have inﬂuenced their perceptions and recall of
the relevant symptoms; untreated participants might have
provided a different perspective.CONCLUSION
The present study represents the ﬁrst step in the development
of the HIS-Q-SF. The results include a draft version of the
instrument comprised of 17 items that ﬁt on a single page and
typically can be completed by patients in less than 2 minutes.
The items, response options, and recall period of the HIS-Q-SF
are suitable, and the content validity has been conﬁrmed. Future
work includes evaluating the psychometric properties of the
instrument and application of the instrument in clinical settings
to assess its utility and value for clinicians. To assess feasibility, it
must be determined whether, in clinical settings, the HIS-Q-SF
can practically and accurately measure symptoms of hypo-
gonadism and detect changes in response to treatment in a way
that is practical and useful in clinical care settings.
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